2 results
Approved WMOCompleted
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
Approved WMORecruiting
Primary Objective: To establish the effectiveness of lavage with needle arthroscopy in patients with suspected bacterial arthritis of a native joint. The primary outcome measure is the number of additional invasive interventions -needle aspiration,…